"description","rationale","label","uuid:ID","name","instanceType","id"
"The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","","c460876a-4e7d-4ffc-b2fd-0e42b8623ccc","Study Design 1","StudyDesign","StudyDesign_1"
